BioCryst Pharmaceuticals Inc
BCRXBioCryst Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing specialty pharmaceuticals for the treatment of rare and infectious diseases. The company primarily develops oral medicines that inhibit specific enzymes involved in disease processes, with a key focus on antiviral and immune modulatory therapies.
Company News
BioCryst announced new clinical data and real-world evidence for ORLADEYO (berotralstat), its oral prophylactic therapy for hereditary angioedema (HAE), showing consistent reductions in HAE attack burden and healthcare utilization. The company also presented post hoc analysis from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, a l...
BioCryst Pharmaceuticals reported Q1 2026 ORLADEYO net revenue of $148.3 million, up 11% year-over-year. The company announced a licensing agreement with Neopharmed Gentili for European commercial rights to navenibart, receiving $70 million upfront and up to $275 million in milestone payments. Patient enrollment in the navenibart pivotal study re...
BioCryst Pharmaceuticals granted an Irish affiliate of Neopharmed Gentili exclusive European rights to commercialize navenibart for hereditary angioedema. BioCryst will receive $70M upfront, up to $275M in future milestone payments, and 18-30% royalties on sales. The agreement builds on their prior ORLADEYO business sale and supports BioCryst's s...
BioCryst Pharmaceuticals announced the appointment of Dr. Sandeep M. Menon as Chief Research and Development Officer. Dr. Menon brings extensive experience from leadership roles at Alnylam Pharmaceuticals and Pfizer, where he oversaw clinical development of multiple therapies including AMVUTTRA and PAXLOVID. The appointment comes as BioCryst adva...
BioCryst Pharmaceuticals announced that its compensation committee granted restricted stock units (RSUs) covering 65,850 shares of common stock to six newly-hired employees as inducement grants. The RSUs vest in four equal annual installments beginning one year from the grant date of March 2, 2026, subject to continued employment.
